Since the use of fluoroquinolone antibiotic in clinical practice was introduced about two decades ago, quinolone-resistant E. coli strains are being isolated with increasing frequency. This study devotes to determine the resistance rate of fluoroquinolones for 112 Escherichia coli isolates from Prince Salman Hospital, Riyadh and to detect the mutations in the quinolone resistance-determining region (QRDR) of gyrA and parC in the fluoroquinolones resistant isolates. The resistance rate of ciprofloxacin for E. coli isolates was 37.5%. We have determined QRDR of the gyrA and parC genes of ciprofloxacin resistant E. coli (MIC 2-64 mg/L). A single mutation in gyrA (Ser TCG-83→ → → →Leu TTG) was detected in the isolate with a reduced susceptibility to ciprofloxacin (MIC 2 mg/L). Three mutations were detected in E. coli isolates with ciprofloxacin MIC ≥16 mg/L. Double mutations in gyrA (Ser-83→ → → →Leu and Asp-87→ → → →Asn) and a single mutation in parC (Ser-80→ → → →Ile). This study suggests, that in clinical isolates of E. coli, DNA gyrase is a primary target of quinolones, that only a single amino acid change at Ser-83 in GyrA is sufficient to generate high-level resistance to nalidixic acid and to decrease susceptibility to ciprofloxacin, and that the accumulation of amino acid changes in GyrA and the simultaneous presence of the ParC alterations play a central role in developing high-level resistance to ciprofloxacin.
INTRODUCTION
Fluoroquinolones are powerful broad-spectrum antibacterial used for the treatment of a wide variety of community-acquired and nosocomial infections (Acar and Goldstein, 1997) . Fluoroquinolones inhibit DNA gyrase and topoisomerase IV activities (Wang et al., 2009) . DNA gyrase is a tetrameric enzyme composed of two GyrA and GyrB subunits, encoded by gyrA and gyrB genes respectively and topoisomerase IV is tetrameric enzyme composed of two ParC and ParE subunits, encoded by parC and parE genes respectively. The main function of DNA gyrase is to catalyze the negative supercoiling of DNA (Hawkey, 2003) while the main action of topo-*Corresponding author. E-mail: elagamy71@yahoo.com. Tel: +966553227824.
Abbreviations: QRDR, Quinolone resistance-determining region; MIC, minimum inhibitory concentration.
isomerase V is to decatenates or removes the interlinking of daughter chromosomes at the completion of a round of DNA replication and allows their segregation into daughter cell (Ambrozic et al., 2007) . Until now three mechanisms of fluoroquinolones resistance were reported: (1) Chromosomal mutations in the gyrA and gyrB of DNA gyrase and in parC and parE of topoisomerase IV, (2) Mutations causing reduced drug accumulation, either by a decreased uptake or by an increased efflux are also involved, (3) Recently, plasmidmediated quinolone resistance (PMQR) mechanisms such as qnr, aac(6')1b-cr and qepA confer low levels of resistance but provide a favorable background in which selection of additional chromosomally encoded quinolone resistance mechanisms can occur (Martínez-Martínez et al., 1998; Wang et al., 2009) . The most important mechanism of quinolone resistance is alteration in the gyrA and gyrB of DNA gyrase and in parC and parE of topoisomerase IV. Alterations in gyrA are reported more often than alteration in gyrB (Frank et al., 2011) . Alterations described in the GyrA are predominantly in the so-called quinolone resistant determining region (QRDR) between positions 67 and 106 (Ambrozic et al., 2007; Vranakis et al., 2010) . The presence of a single mutation in the QRDR of gyrA usually results in high level resistance to nalidixic acid, but to obtain high levels of resistance to fluoroquinolones, the presence of additional mutation(s) in gyrA and/or in another target such as parC is required. Thus, it has been proposed that the MIC of nalidixic acid could be used as a genetic marker of resistance for quinolone family in Gram-negative bacteria (Ruiz, 2003) . Quinolone resistance genes associated with plasmids have been also described, that is, the qnr gene that encodes a pentapeptide, which blocks the action of quinolones on the DNA gyrase and topoisomerase IV; the aac(6')-Ib-cr gene that encodes an acetylase that modifies the amino group of the piperazin ring of the fluoroquinolones and efflux pump encoded by the qepA gene that decreases intracellular drug levels (Fàbrega et al., 2009 ).
To our knowledge, there is no study aimed to understand the molecular resistance mechanism to quinolones in Escherichia coli strains isolated from Saudi Arabia. Therefore, this study was undertaken to determine the mechanism of quinolone resistance in E. coli isolates from Riyadh.
MATERIALS AND METHODS

Bacterial strains
One hundred and twelve non-duplicate, non-consecutive urinary clinical E. coli isolates were collected between January to March, 2010 from Prince Salman Hospital, Riyadh. The laboratory strain; E. coli ATCC 29525, was used as standard control in sensitivity testing. E. coli isolates were identified according to a commercial identification system of Micronaut-IDS (MERLIN Diagnostika, Germany).
Antimicrobial susceptibility testing
MICs for 112 E. coli isolates were determined in a broth microdilution test, using unsupplemented Mueller Hinton broth, according to the recommendation of clinical and laboratory standards institutes (CLSI, 2006) using Micronaut microtiter plates containing dehydrated antibiotics (Merlin Diagnostika, Germany) in two-fold dilution. The following quinolones were tested: ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin, pimpedic acid and sparfloxacin.
DNA template preparation
DNA templates were prepared from 200 µl volume of overnight culture of the test isolates in Luria Beratni broth (Difco, USA) by centrifugation using microfuge tubes and resuspending the bacterial pellet to the initial volume with distilled water. The template DNA was prepared by boiling for 10 min and directly used in the PCR assay.
Amplification of QRDR in gyrA and parC gene subunits
Amplification of QRDR in gyrA and parC gene subunits in quinolone-resistant clinical isolates of E. coli was done by polymerase chain reaction (PCR) according to methods described by Grigges et al. (1996) and Heisig (1996) . Oligonucleotides used in this study are listed in Table 1 . Reactions were run with Techne thermocycler (Techne, UK). The PCR products were electrophoresed in 0.7% agarose gels containing ethidium bromide 0.5 mg/L, the DNA fragments were photographed with video documentation system.
Sequencing of gyrA and parC gene subunits
Amplicons of gyrA and parC were purified with a QIAquick PCR purification kit (Qiagen, Hilden, Germany) and were subjected to direct sequencing reactions on both strands using the primers listed in Table 1 by dideoxy chain terminator method of Sanger et al. (1977) on an API310 automatic sequencer analyzer using API PRISM dye Terminator Cycle Sequencing Ready Reaction kit with AmpliTaq DNA polymerase FS (Perkin-Elmer/ Applied Biosystems, Foster City, CA, USA).
RESULTS
Antimicrobial susceptibility testing
The results of MICs for 112 E. coli isolates to ciprofloxacin are shown in Table 1 . The susceptibility of Table 2 . 42 (37.5%) and 12 (10.71%) out of 112 E. coli isolates represented a lowest ciprofloxacin MIC (<0.0625 and 0.0625 mg/L respectively) whereas, 16 (14.28%) and 20 (17.85%) out of 112 E. coli isolates showed a highest ciprofloxacin MIC (32 and 64 mg/L respectively). However, the remaining 20 (17.85%) isolates showed ciprofloxacin MIC values ranging from 0.5 to 16 µg/ml. The MIC resistance breakpoints to ciprofloxacin are ≥ 4 mg/L. Four E. coli isolates with different ciprofloxacin MICs, 2, 16, 32 and 64 mg/L respectively were selected in this study to perform gyrA and parC sequence.
Determination of mechanisms of E. coli resistance to quinolones
The results of mutations in gyrA and parC subunits are shown in Table 3 . The QRDR of gyrA subunit of three quinolone resistant E. coli isolates (Ciprofloxacin MIC≥ 16 mg/L) and one quinolone moderately resistant isolate (ciprofloxacin MIC 2 mg/L) was amplified. The purified QRDR of gyrA subunit for four E. coli isolates, with different ciprofloxacin MIC values 2, 16, 32 and 64 mg/L, were sequenced on both strands with specific primers. The results of nucleotide sequence of the QRDR of gyrA subunit for the E. coli isolates using the forward primer, P1 and reverse primer, P2BIO, revealed that single mutation in gyrA at codon 83 (Ser TCG→Leu, TTC) was observed in isolate with a reduced susceptibility to ciprofloxacin (MIC 2 mg/L). A nucleotide number 248 of gyrA exchanged from C to T, which subsequently exchanged amino acid from serine into leucin. Whereas, double mutations in gyrA at codon 83 (Ser TCG→Leu, TTC) and 87 (Asp GAC→Asn, AAC) were recorded in E. coli isolates with full resistance to ciprofloxacin. A nucleotide number 259 of gyrA exchanged from G to A, which subsequently exchanged amino acid from aspartic acid into asparagine.
The QRDR of parC subunit of topoisomerase IV of ciprofloxacin resistant E. coli isolates (MIC ≥16 mg/L) and of ciprofloxacin moderately resistant isolate with MIC equal to 2 mg/L was amplified. The purified QRDR of parC subunit for the tested four E. coli isolates were sequenced on both strands with specific primers. The results of nucleotide sequence of QRDR of parC subunit of three isolates resistant to ciprofloxacin using the forward primer, ParC-S and reverse primer, parC-U, revealed that no mutation in parC was observed in the isolate with a reduced susceptibility to ciprofloxacin (MIC 2 mg/L) whereas a single mutation in parC at codon 80 (Ser AGC→Ile ATC) were recorded in E. coli isolates with full resistance to ciprofloxacin. A nucleotide A was exchanged into G at codon 80, which subsequently exchanged amino acid from serine into isoleucine. The codon number 91, CAA, of parC subunit, which translated into glutamine of E 2 was exchanged into CAG in parC of E 5 but this mutation was silent.
DISCUSSION
Increasing bacterial resistance has followed this widespread use that specifically target bacterial DNA gyrase and topoisomerase IV. However, resistance to fluoroquinolones has increased markedly since introduction in the late 1980s (Aguiar et al., 1992) .
In the present study ciprofloxacin resistant E. coli was 38.5%, while the previous studies in Saudi Arabia, reported high levels of resistance to ciprofloxacin (60 to 80%) in Enterobacteriaceae (Al Johani et al., 2010; Khanfar et al., 2009 ) and other studies showed low level of ciprofloxacin resistance in Klebsiella pneumoniae from Al-Qassim (9.1%) and Riyadh (11%), Saudi Arabia (Tawfik et al., 2011; Al-Agamy et al., 2009) . The difference in the resistance pattern could be due to differences in isolation dates, localities, rate of consumption of fluoroquinolones in the different hospitals…etc. The rate of E. coli resistance to fluoroquinolones is increasing worldwide. In USA the rate of resistance in E. coli isolates was 3.5% and 1.9 to 2.5% for nalidixic acid and fluoroquinolones respectively (Karlowsky et al., 2003) .
The association of DNA gyrase and topoisomerase IV mutations with fluoroquinolones resistance has been established for both Gram-negative and Gram-positive organisms (Frank et al., 2011) . Accumulation of alterations in gyrA and the simultaneous presence alterations in parC play fundamental role in developing high level of resistance to ciprofloxacin in clinical isolates. Point mutations in gyrA of Ser-83 to either Try or Leu, both of which convert the polar amino acid serine to nonpolar amino acid tyrosine (Conrad et al., 1996) or double mutations of Ser-83→Leu and Asp-87→Gly (Vila et al., 1994) , are the most frequent bases for the fluoroquinolones resistant in E. coli isolates. In addition, mutations in parC at Ser-80, Gly-78, and Glu-84 have been also been noted (Kumagai et al., 1996) .
In the present study, four E. coli isolates with different ciprofloxacin MIC values ranged from 2 to 64 mg/L were selected [E 2 (MIC 2 mg/L), E 43 (MIC 16 mg/L), E 8 (MIC 32 mg/L), and E 5 (MIC 64 mg/L)] to amplify and sequence of QRDR of gyrA and parC. A single mutation was detected Al-Agamy et al. 1057 in gyrA (Ser-83→Leu) of E. coli isolate E 2 (Ciprofloxacin MIC 2 mg/L) and this mutation led to decrease the susceptibility to ciprofloxacin. In the E. coli isolates E 43 , E 8 and E 5 with ciprofloxacin MIC values of 16, 32, and 64 mg/L respectively; three mutations were detected, two mutations in gyrA (Ser-83→Leu and Asp-87→Asn) and a single mutation in parC (Ser-80→Ile). These mutations were responsible for high resistance of the isolates to fluoroquinolones. Wiegel et al. (1998) reported in E. coli, a C-to-T substitution at the second position of the codon, resulting in a Ser-83-to-Leu mutation, was consistent for all fluoroquinolone-resistant isolates. The present study agreed with the study reported by Wiegel et al. (1998) . In the present study, a nucleotide number 248 of gyrA exchanged from C to T, which subsequently exchanged amino acid from serine into leucin. In the isolates with double mutations, the second alteration involved the codon for Asp-87 and the amino acid substitution was Gly, Tyr, or Asn. A single mutation in codon 83 of gyrA was associated with decreased susceptibility or low levels of resistance to fluoroquinolones, and double mutations (codons 83 and 87) were associated with high levels of resistance. The highest level of resistance to fluoroquinolones (> 64 mg/L) was not detected in this study because this resistance generally results from four mutations: two in gyrA and two in parC (Vila et al., 1994; Sáenz et al., 2003) and this was not detected in the present study.
In summary, the rate of E. coli resistance to fluoroquinolones is increasing in Saudi Arabia and this finding indicates alarmingly that the fluoroquinolones will become useless within the next few years in Saudi Arabia. This data extends our understanding of the molecular mechanisms of fluoroquinolones resistance associated with gyrA and parC mutations in E. coli isolated from Saudi Arabia.
